This review seeks to provide an overview of its role in DS tumors, including but not limited to esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), and pancreatic ductal adenocarcinoma (PDAC), in the hope of promoting research on the clinical applications of ANXA2. This evidence concerns the gene ANXA2 and colorectal carcinoma.